VHL Loss-of-function

CI-VAR-00002521Explore in graph →CIViC 159

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Clear Cell Renal Cell Carcinoma1
VHL Loss-of-function	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID428 In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival. PMID 11793370 · Schraml et al., 2002 · Open in CIViC	civic
Renal Cell Carcinoma1
VHL Loss-of-function	Temsirolimus	Predictive	D	Supports Sensitivity Response	3	submitted	EID4828 A preclinical study to show sensitization to mTOR inhibition with Temsirolimus in renal cell carcinoma cells and a mouse mode showing a VHL loss of function. Growth arrest caused by Temsirolimus corr… (full text at CIViC) PMID 16341243 · Thomas et al., 2006 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.